Physician profile
Hunter Mitchell
NPI 1427614692
$872.49
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $673 · 2024: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $293.47 | 2023-2024 | Austedo Xr, Ajovy |
| Lilly USA, LLC | $155.54 | 2023-2024 | Reyvow, Emgality, Amyvid |
| Jazz Pharmaceuticals INC. | $123.26 | 2023 | |
| Abbvie INC. | $68.57 | 2023 | |
| Lundbeck LLC | $58.51 | 2023 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $30.56 | 2024 | Rexulti |
| Catalyst Pharmaceuticals, INC. | $28.12 | 2023 | Firdapse |
| Novo Nordisk INC | $22.61 | 2023 | Wegovy |
| Alexion Pharmaceuticals, INC. | $20.65 | 2024 | Soliris |
| Tanabe Pharma America, INC. | $19.10 | 2024 | |
| Horizon Therapeutics Plc | $17.96 | 2023 | |
| Ucb, INC. | $17.42 | 2024 | Briviact |
| Merck Sharp & Dohme LLC | $16.72 | 2023 | Welireg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.